Scilex Holding Company
Scilex Holding Company (SCLXW) Stock Competitors & Peer Comparison
See (SCLXW) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SCLXW | $0.16 | -5.27% | 1.4M | N/A | N/A | N/A |
| LLY | $883.96 | -3.67% | 835.4B | 38.54 | $22.94 | +0.70% |
| JNJ | $227.50 | -1.37% | 548.1B | 20.60 | $11.04 | +2.28% |
| ABBV | $198.71 | -1.11% | 351.4B | 83.47 | $2.38 | +3.39% |
| AZN | $189.75 | -1.33% | 294.1B | 29.00 | $6.54 | +1.69% |
| NVS | $145.47 | -1.36% | 280.7B | 20.34 | $7.15 | +3.28% |
| MRK | $111.90 | -2.37% | 276.6B | 15.37 | $7.28 | +2.97% |
| AMGN | $344.55 | -1.17% | 185.7B | 24.18 | $14.25 | +2.79% |
| NVO | $41.16 | +6.87% | 182.9B | 11.40 | $3.61 | +4.53% |
| GILD | $130.40 | -2.42% | 161.7B | 15.99 | $8.15 | +2.45% |
Stock Comparison
SCLXW vs LLY Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, LLY has a market cap of 835.4B. Regarding current trading prices, SCLXW is priced at $0.16, while LLY trades at $883.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas LLY's P/E ratio is 38.54. In terms of profitability, SCLXW's ROE is +1.90%, compared to LLY's ROE of +0.98%. Regarding short-term risk, SCLXW is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check LLY's competition here
SCLXW vs JNJ Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, JNJ has a market cap of 548.1B. Regarding current trading prices, SCLXW is priced at $0.16, while JNJ trades at $227.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas JNJ's P/E ratio is 20.60. In terms of profitability, SCLXW's ROE is +1.90%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, SCLXW is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check JNJ's competition here
SCLXW vs ABBV Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, ABBV has a market cap of 351.4B. Regarding current trading prices, SCLXW is priced at $0.16, while ABBV trades at $198.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas ABBV's P/E ratio is 83.47. In terms of profitability, SCLXW's ROE is +1.90%, compared to ABBV's ROE of -3.62%. Regarding short-term risk, SCLXW is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check ABBV's competition here
SCLXW vs AZN Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, AZN has a market cap of 294.1B. Regarding current trading prices, SCLXW is priced at $0.16, while AZN trades at $189.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas AZN's P/E ratio is 29.00. In terms of profitability, SCLXW's ROE is +1.90%, compared to AZN's ROE of +0.23%. Regarding short-term risk, SCLXW is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check AZN's competition here
SCLXW vs NVS Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, NVS has a market cap of 280.7B. Regarding current trading prices, SCLXW is priced at $0.16, while NVS trades at $145.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas NVS's P/E ratio is 20.34. In terms of profitability, SCLXW's ROE is +1.90%, compared to NVS's ROE of +0.33%. Regarding short-term risk, SCLXW is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check NVS's competition here
SCLXW vs MRK Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, MRK has a market cap of 276.6B. Regarding current trading prices, SCLXW is priced at $0.16, while MRK trades at $111.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas MRK's P/E ratio is 15.37. In terms of profitability, SCLXW's ROE is +1.90%, compared to MRK's ROE of +0.36%. Regarding short-term risk, SCLXW is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check MRK's competition here
SCLXW vs AMGN Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, AMGN has a market cap of 185.7B. Regarding current trading prices, SCLXW is priced at $0.16, while AMGN trades at $344.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas AMGN's P/E ratio is 24.18. In terms of profitability, SCLXW's ROE is +1.90%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, SCLXW is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check AMGN's competition here
SCLXW vs NVO Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, NVO has a market cap of 182.9B. Regarding current trading prices, SCLXW is priced at $0.16, while NVO trades at $41.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas NVO's P/E ratio is 11.40. In terms of profitability, SCLXW's ROE is +1.90%, compared to NVO's ROE of +0.61%. Regarding short-term risk, SCLXW is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check NVO's competition here
SCLXW vs GILD Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, GILD has a market cap of 161.7B. Regarding current trading prices, SCLXW is priced at $0.16, while GILD trades at $130.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas GILD's P/E ratio is 15.99. In terms of profitability, SCLXW's ROE is +1.90%, compared to GILD's ROE of +0.41%. Regarding short-term risk, SCLXW is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check GILD's competition here
SCLXW vs PFE Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, PFE has a market cap of 153.5B. Regarding current trading prices, SCLXW is priced at $0.16, while PFE trades at $27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas PFE's P/E ratio is 19.84. In terms of profitability, SCLXW's ROE is +1.90%, compared to PFE's ROE of +0.09%. Regarding short-term risk, SCLXW is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check PFE's competition here
SCLXW vs BMY Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, BMY has a market cap of 119.9B. Regarding current trading prices, SCLXW is priced at $0.16, while BMY trades at $58.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas BMY's P/E ratio is 16.97. In terms of profitability, SCLXW's ROE is +1.90%, compared to BMY's ROE of +0.39%. Regarding short-term risk, SCLXW is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check BMY's competition here
SCLXW vs SNY Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, SNY has a market cap of 113B. Regarding current trading prices, SCLXW is priced at $0.16, while SNY trades at $46.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas SNY's P/E ratio is 20.16. In terms of profitability, SCLXW's ROE is +1.90%, compared to SNY's ROE of +0.11%. Regarding short-term risk, SCLXW is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check SNY's competition here
SCLXW vs GSK Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, GSK has a market cap of 109.6B. Regarding current trading prices, SCLXW is priced at $0.16, while GSK trades at $54.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas GSK's P/E ratio is 14.55. In terms of profitability, SCLXW's ROE is +1.90%, compared to GSK's ROE of +0.30%. Regarding short-term risk, SCLXW is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check GSK's competition here
SCLXW vs BIIB Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, BIIB has a market cap of 27.1B. Regarding current trading prices, SCLXW is priced at $0.16, while BIIB trades at $184.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas BIIB's P/E ratio is 20.95. In terms of profitability, SCLXW's ROE is +1.90%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, SCLXW is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check BIIB's competition here
SCLXW vs HZNP Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, SCLXW is priced at $0.16, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas HZNP's P/E ratio is 61.86. In terms of profitability, SCLXW's ROE is +1.90%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, SCLXW is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check HZNP's competition here
SCLXW vs GRFS Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, SCLXW is priced at $0.16, while GRFS trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas GRFS's P/E ratio is 11.71. In terms of profitability, SCLXW's ROE is +1.90%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, SCLXW is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check GRFS's competition here
SCLXW vs OGN Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, OGN has a market cap of 2.9B. Regarding current trading prices, SCLXW is priced at $0.16, while OGN trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas OGN's P/E ratio is 15.67. In terms of profitability, SCLXW's ROE is +1.90%, compared to OGN's ROE of +0.26%. Regarding short-term risk, SCLXW is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check OGN's competition here
SCLXW vs CELG-RI Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, CELG-RI has a market cap of 163.5M. Regarding current trading prices, SCLXW is priced at $0.16, while CELG-RI trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, SCLXW's ROE is +1.90%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, SCLXW is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check CELG-RI's competition here
SCLXW vs CTOR Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, CTOR has a market cap of 77.4M. Regarding current trading prices, SCLXW is priced at $0.16, while CTOR trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -2.83. In terms of profitability, SCLXW's ROE is +1.90%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, SCLXW is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check CTOR's competition here
SCLXW vs SCLX Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, SCLX has a market cap of 56.8M. Regarding current trading prices, SCLXW is priced at $0.16, while SCLX trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas SCLX's P/E ratio is -0.18. In terms of profitability, SCLXW's ROE is +1.90%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, SCLXW is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check SCLX's competition here
SCLXW vs MIRA Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, MIRA has a market cap of 44.1M. Regarding current trading prices, SCLXW is priced at $0.16, while MIRA trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas MIRA's P/E ratio is -0.78. In terms of profitability, SCLXW's ROE is +1.90%, compared to MIRA's ROE of -6.46%. Regarding short-term risk, SCLXW is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check MIRA's competition here
SCLXW vs SRXH Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, SRXH has a market cap of 4.1M. Regarding current trading prices, SCLXW is priced at $0.16, while SRXH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas SRXH's P/E ratio is -0.71. In terms of profitability, SCLXW's ROE is +1.90%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, SCLXW is more volatile compared to SRXH. This indicates potentially higher risk in terms of short-term price fluctuations for SCLXW.Check SRXH's competition here
SCLXW vs BDSIW Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, SCLXW is priced at $0.16, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas BDSIW's P/E ratio is N/A. In terms of profitability, SCLXW's ROE is +1.90%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, SCLXW is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check BDSIW's competition here
SCLXW vs CRXT Comparison April 2026
SCLXW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCLXW stands at 1.4M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, SCLXW is priced at $0.16, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCLXW currently has a P/E ratio of N/A, whereas CRXT's P/E ratio is -0.02. In terms of profitability, SCLXW's ROE is +1.90%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, SCLXW is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for SCLXW.Check CRXT's competition here